Michael Secora - 16 Oct 2026 Form 4 Insider Report for Iambic Therapeutics, Inc. (IAM)

Reporting relationship: CFO & Chief Corp Dev Ofcr
Issuer ticker: IAM
Reported as of: 16 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Oct 2026, 19:51:37 UTC
Prior SEC filing: 14 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Sunny Chang, by power of attorney

Filing notes and source

Key filing fact

Michael Secora filed Form 4 for Iambic Therapeutics, Inc. (IAM) on 19 Oct 2026.

Key facts

This page summarizes Michael Secora's Form 4 filing for Iambic Therapeutics, Inc. (IAM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Oct 2026, 19:51.

Change

Previous filing in this sequence was filed on 14 Oct 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001855980 Primary reporting owner

Secora Michael

Relationship: CFO & Chief Corp Dev Ofcr
Address: C/O IAMBIC THERAPEUTICS, INC., 5627 OBERLIN DRIVE, SUITE 120, SAN DIEGO
Signature: /s/ Sunny Chang, by power of attorney
Signature date: 19 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IAM transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +61,342
Change %: +28%
Price
Shares after: 279,902
Date: 16 Oct 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IAM transaction Derivative

Series B-3 Convertible Preferred Stock

Conversion of derivative security

Transaction value
Shares: -61,342
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 16 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 61,342
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of Series B-3 Convertible Preferred Stock automatically converted into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.